Showing results (1-10 of 72) with videos related to
Sort By:
Pageof 8
Journal of Clinical Pharmacology|December 8, 2009
Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairmentWilliam Smith, Suzanne Swan, Thomas Marbury, et al.Drug Design, Development and Therapy|March 1, 2017
Pharmacokinetics of conivaptan use in patients with severe hepatic impairmentThomas Marbury, Jerry Fox, Byron Kaelin, et al.Journal of Clinical Pharmacology|December 26, 2009
Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well-controlled end-stage renal disease (ESRD)Allen Radin, Thomas Marbury, Greg Osgood, et al.Journal of Clinical Pharmacology|March 26, 2009
Pharmacokinetics of dalbavancin in patients with renal or hepatic impairmentThomas Marbury, James A Dowell, Elyse Seltzer, et al.Journal of Cardiovascular Pharmacology|November 29, 2012
Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysisAmanda Jenkins, Laurene Wang-Smith, Thomas Marbury, et al.Journal of Diabetes Science and Technology|February 10, 2011
Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjectsRobert Stote, Michael Miller, Thomas Marbury, et al.Journal of Diabetes Science and Technology|June 2, 2010
Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulationRobert Stote, Thomas Marbury, Leon Shi, et al.Clinical Therapeutics|November 1, 2015
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical StudiesPaul Martin, Stuart Oliver, Michael Gillen, et al.Journal of Clinical Pharmacology|March 14, 2019
Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring HemodialysisKatie Zomorodi, Dan Chen, Lawrence Lee, et al.BMC Nephrology|October 14, 2024
Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritusRobert H Spencer, Patrick K Noonan, Thomas Marbury, et al.Pageof 8